博雅生物

300294 SZSE 证监会行业分类 C27医药制造业

Key Metrics

Market Cap

9.8B ($1.4B)

P/E Ratio

N/A

P/B Ratio

N/A

Revenue

2.1B

Net Income

113.0M

Gross Margin

N/A

Op. Margin

5.3%

Net Margin

5.5%

ROE

1.5%

ROA

1.3%

D/E

0.16

Dividend Yield

N/A

EPS

0.22

Current Ratio

5.06

Price History

Company Info

Industry	C27医药制造业
Market Segment	ChiNext
Currency	CNY
Fiscal Year	2025

Business Overview

China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the blood product businesses in China. It offers blood products, such as human coagulation, human prothrombin, human fibrinogen, human albumin, intravenous human immunoglobulin, and rabies immunoglobulin; and non-blood products. The company also provides bone peptide, oxytocin, heparin sodium, and posterior pituitary injection products. In addition, it engages in research, development, production, and sales of anti-infective, diabetes, and cardiovascular drug; and distributes blood products. The company was formerly known as Boya...

Full Financials Advanced Charts Filings

Peers

工商银行

601398

2.7T

P/E: 7.6

建设银行

601939

2.5T

P/E: 7.2

农业银行

601288

2.4T

P/E: 8.7

中国海油

600938

2.0T

P/E: 16.2

宁德时代

300750

1.9T

P/E: 25.6

贵州茅台

600519

1.8T

P/E: 20.1

中国银行

601988

1.8T

P/E: 7.3

中国人寿

601628

1.2T

P/E: 6.9

Financial Statements

Loading financials...

Open Advanced Charts

Full charting with technical indicators, candlestick, and more.

About 博雅生物

Ticker	300294
Exchange	SZSE
Sector	证监会行业分类
Industry	C27医药制造业